Adverse Event reporting information can be found in footer

Request a Meeting

PI
Firmagon degarelix. Think beyond the prostate Icon Icon Icon Icon

The economic burden of CVD in the UK

FIRMAGON® reduces the risk of CV events vs. LHRH agonists1-5,15
Learn More...
How much are CVD-related healthcare costs estimated to be annually in each UK country?6,7
Hover over the map to find out
£800 million annually in Scotland, Data for England suggests that one event costs an estimated average of £3,449.2,3
£412 million annually for Northern Ireland. Data for England suggests that one event costs an estimated average of £3,449.2,3
£550 million annually in Wales,
Data for England suggests that one event costs an estimated average of £3,449.2,3
£7.4 billion annually in England3,
with one event costing an estimated average of £3,4492,3

If you would like access your local ICS level data…

Tools to help manage cardiovascular risk in your patients

To minimise the number of CV events, risk assessment and risk-reduction measures are important prior to starting ADT.9-10

Below you can find both the STAMP tool and the CV risk assessment tool to help you assess your prostate cancer patients.

STAMP - Identification of patients with CVD11

S
Stroke
T
Transient ischaemic attack
A
Abdominal aortic aneurysm or other aortic disease
M
Myocardial infarction, angina, or previous coronary revascularisation
P
Peripheral arterial disease
Guideline-recommended interventions for men with PCa at high CV risk
EAU GUIDELINES12

“There is a suggestion in some studies and a SR and meta-analysis that cardiovascular side effects are less frequent in patients treated with LHRH antagonists than patients treated with LHRH agonists therefore patients with pre-existing cardiovascular disease or other cardiovascular risk factors might be considered to be treated with antagonists if a chemical castration is chosen”.

CUA GUIDELINES13

Use of a GnRH antagonist may be considered in men with a prior history of myocardial infarction or stroke, or with significant cardiac comorbidities

“It might be time to consider treating men who have pre-existing CV risk factors with a GnRH antagonist rather than an agonist.’’ 14

The CV risk assessment tool10

CV risk assessment tool

Adapted from Davey P and Alexandrou P. 202210

▲ SECTION NAVIGATION ▲